Fate Therapeutics(FATE),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community - To The Moon

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

FATE Fate Therapeutics

Trading 05-21 14:22:08 EDT

2.09

+0.25

+13.32%

High2.11	Low1.79	Vol3.35M
Open1.79	D1 Closing1.84	Amplitude17.66%
Mkt Cap242.41M	Tradable Cap210.16M	Total Shares116.26M
T/O6.76M	T/O Rate3.32%	Tradable Shares100.80M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Loading ...

{"stockData":{"symbol":"FATE","market":"US","secType":"STK","nameCN":"Fate Therapeutics","latestPrice":2.085,"timestamp":1779387727153,"preClose":1.84,"halted":0,"volume":3345008,"delay":0,"changeRate":0.1331521739130434,"floatShares":100797117,"shares":116263459,"eps":-1.089789,"marketStatus":"Trading","change":0.245,"latestTime":"05-21 14:22:08 EDT","open":1.79,"high":2.11,"low":1.785,"amount":6757784.524076801,"amplitude":0.17663,"askPrice":2.09,"askSize":2492,"bidPrice":2.08,"bidSize":488,"shortable":3,"etf":0,"ttmEps":-1.089789,"tradingStatus":2,"nextMarketStatus":{"tag":"Post-Mkt","tradingStatus":3,"beginTime":1779393600000},"marketStatusCode":2,"adr":0,"adrRate":0,"listingDate":1380600000000,"exchange":"NASDAQ","adjPreClose":1.84,"preHourTrading":{"tag":"盘前","latestPrice":1.86,"preClose":1.84,"latestTime":"09:29 EDT","volume":66,"amount":122.76,"timestamp":1779370148936,"change":0.02,"changeRate":0.01087,"amplitude":0},"postHourTrading":{"tag":"盘后","latestPrice":1.8846,"preClose":1.84,"latestTime":"19:56 EDT","volume":48297,"amount":89001.8283,"timestamp":1779321400143,"change":0.0446,"changeRate":0.024239,"amplitude":0.038043},"volumeRatio":1.335218,"impliedVol":1.4162,"impliedVolPercentile":0.7131},"requestUrl":"/m/hq/s/FATE/wiki","defaultTab":"wiki","newsList":[{"id":"2637335423","title":"Fate Therapeutics Announces Presentations at 2026 Asco and Eular Annual Meetings Highlighting off-the-Shelf Car T-Cell Therapy Pipeline for Cancer and Autoimmune Diseases","url":"https://stock-news.laohu8.com/highlight/detail?id=2637335423","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2637335423?lang=en_us&edition=fundamental","pubTime":"2026-05-21 20:30","pubTimestamp":1779366600,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260521:nTUA4VCHQ1:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","FATE"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2637335005","title":"Fate Therapeutics Announces Presentations at 2026 ASCO and EULAR Annual Meetings Highlighting Off-the-Shelf CAR T-cell Therapy Pipeline for Cancer and Autoimmune Diseases","url":"https://stock-news.laohu8.com/highlight/detail?id=2637335005","media":"GlobeNewswire","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2637335005?lang=en_us&edition=fundamental","pubTime":"2026-05-21 20:30","pubTimestamp":1779366600,"startTime":"0","endTime":"0","summary":"SAN DIEGO, May  21, 2026  (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to bringing a transformative pipeline of induced pluripotent ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/05/21/3299320/24675/en/Fate-Therapeutics-Announces-Presentations-at-2026-ASCO-and-EULAR-Annual-Meetings-Highlighting-Off-the-Shelf-CAR-T-cell-Therapy-Pipeline-for-Cancer-and-Autoimmune-Diseases.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4022","FATE","BK4139","CAR","BK4230"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2636869410","title":"Fate Therapeutics assumed with a Buy at Jefferies","url":"https://stock-news.laohu8.com/highlight/detail?id=2636869410","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2636869410?lang=en_us&edition=fundamental","pubTime":"2026-05-20 03:15","pubTimestamp":1779218109,"startTime":"0","endTime":"0","summary":"Jefferies assumed coverage of Fate Therapeutics (FATE) with a Buy rating and $4 price target Lead program FAT819 is in Phase 1 for various autoimmu...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/fate-therapeutics-assumed-with-a-buy-at-jefferies-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/fate-therapeutics-assumed-with-a-buy-at-jefferies-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["FATE","BK4139","DBB"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2635635714","title":"Wells Fargo Remains a Hold on Fate Therapeutics (FATE)","url":"https://stock-news.laohu8.com/highlight/detail?id=2635635714","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2635635714?lang=en_us&edition=fundamental","pubTime":"2026-05-14 19:37","pubTimestamp":1778758650,"startTime":"0","endTime":"0","summary":"Wells Fargo analyst maintained a Hold rating on Fate Therapeutics today and set a price target of $2.50. In addition to Wells Fargo, Fate Therapeut...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/wells-fargo-remains-a-hold-on-fate-therapeutics-fate-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/wells-fargo-remains-a-hold-on-fate-therapeutics-fate-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4504","LU1668664300.SGD","LU0154236417.USD","LU0208291251.USD","IE00B7SZLL34.SGD","LU1506573853.SGD","LU1074936037.SGD","LU0742534661.SGD","LU0310800965.SGD","LU0310800379.SGD","BK4588","LU1363072403.SGD","LU0314106906.USD","LU0708994859.HKD","LU0320765489.SGD","LU0251131958.USD","LU1791807156.HKD","LU0162691827.USD","LU0128525689.USD","BK4582","LU2361045086.USD","LU0106831901.USD","LU0130102774.USD","LU0289960550.SGD","LU2236285917.USD","LU1267930490.SGD","LU0070302665.USD","LU1280957306.USD","LU0971096721.USD","FATE","LU0648001328.SGD","LU0267386448.USD","LU0868494708.USD","LU1894683264.USD","LU0251142724.SGD","LU1894683348.USD","LU0942090050.USD","IE000M9KFDE8.USD","BK4559","LU0980610538.SGD","LU0130517989.USD","IE00B19Z3B42.SGD","LU1035773651.USD","PGF","BK4501","BK4585","IE0002270589.USD","LU0029864427.USD","LU1201861249.SGD","LU0787776722.HKD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2635973603","title":"Fate Therapeutics reports Q1 EPS (26c), consensus (28c)","url":"https://stock-news.laohu8.com/highlight/detail?id=2635973603","media":"TIPRANKS","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2635973603?lang=en_us&edition=fundamental","pubTime":"2026-05-13 23:28","pubTimestamp":1778686137,"startTime":"0","endTime":"0","summary":"Reports Q1 revenue $1.3M, consensus $1.55M. “We are incredibly excited and focused on initiating RECLAIM-LN, our Phase 2 potentially registrational...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/fate-therapeutics-reports-q1-eps-26c-consensus-28c-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/fate-therapeutics-reports-q1-eps-26c-consensus-28c-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["FATE"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2635078742","title":"Fate Therapeutics Inc reports results for the quarter ended March 31 - Earnings Summary","url":"https://stock-news.laohu8.com/highlight/detail?id=2635078742","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2635078742?lang=en_us&edition=fundamental","pubTime":"2026-05-13 21:03","pubTimestamp":1778677436,"startTime":"0","endTime":"0","summary":"Fate Therapeutics Inc reports results for the quarter ended March 31 - Earnings SummaryFate Therapeutics Inc FATE.OQ reported a quarterly adjusted loss of 26 cents per share for the quarter ended Marc","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260513:nL8N41Q1Q3:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["FATE","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2635782213","title":"Fate Therapeutics Q1 operating loss narrows, cash runway extended into 2028","url":"https://stock-news.laohu8.com/highlight/detail?id=2635782213","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2635782213?lang=en_us&edition=fundamental","pubTime":"2026-05-13 20:40","pubTimestamp":1778676014,"startTime":"0","endTime":"0","summary":"Fate Therapeutics Q1 operating loss narrows, cash runway extended into 2028OverviewBiopharmaceutical firm's Q1 collaboration revenue declined yr/yrQ1 operating expenses fell 20% from prior year, exten","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260513:nL1N41Q0LR:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","FATE"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2635782600","title":"Fate Therapeutics Q1 EPS $(0.26) Beats $(0.28) Estimate, Sales $1.299M Beat $1.139M Estimate","url":"https://stock-news.laohu8.com/highlight/detail?id=2635782600","media":"Benzinga","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2635782600?lang=en_us&edition=fundamental","pubTime":"2026-05-13 20:33","pubTimestamp":1778675584,"startTime":"0","endTime":"0","summary":"Fate Therapeutics (NASDAQ:FATE) reported quarterly losses of $(0.26) per share which beat the analyst consensus estimate of $(0.28) by 7.14 percent. This is a 18.75 percent increase over losses of $(0.32) per share from","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":"11c8fbbf839f433c9d274cef5f173382","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/news/earnings/26/05/52520159/fate-therapeutics-q1-eps-0-26-beats-0-28-estimate-sales-1-299m-beat-1-139m-estimate","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["FATE"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2635782627","title":"Fate Therapeutics Q1 FY26 net loss narrows 17.04% to $31.21 million","url":"https://stock-news.laohu8.com/highlight/detail?id=2635782627","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2635782627?lang=en_us&edition=fundamental","pubTime":"2026-05-13 20:32","pubTimestamp":1778675533,"startTime":"0","endTime":"0","summary":"Fate Therapeutics posted a first-quarter net loss of USD 31.21 million, narrowing from USD 37.62 million a year earlier, while operating loss improved to USD 33 million from USD 41.28 million.Revenue slipped to USD 1.3 million from USD 1.63 million, while total operating expenses fell 20% year over year to USD 34.3 million.Cash, cash equivalents, and investments totaled USD 174.8 million at March 31, supporting an operating runway into 2028.RECLAIM-LN, a Phase 2 potentially registrational trial of FT819 in lupus nephritis, remained on track to start patient dosing in second-half 2026, targeting about 53 patients and using a single 900 million-cell dose following bendamustine conditioning.FT819 was selected for FDA CDRP participation to increase CMC-focused interactions, while FT839 IND filing and Phase 1 enrollment are planned for second-half 2026 and FT836 Phase 1 study had treated nine patients as of April 20 with updated data expected at ASCO in June.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260513:nNDL8Ds2wD:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00BKPKM429.USD","LU2095319765.USD","BK4585","IE00BN0W2W23.USD","IE00BGHQF748.EUR","LU2210149790.SGD","SG9999014005.SGD","BK4588","LU2210150020.SGD","LU0314104364.USD","NDAQ","FATE","IE00BN0W2T93.GBP","IE00B64PRP62.GBP","IE00BN0W2V16.EUR","SG9999014013.SGD","BK4139","BK4112","SG9999014021.USD","IE00B3QW5Z07.USD","SG9999014039.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2635782592","title":"Fate Therapeutics Q1 Operating Expenses USD 34.299 Million","url":"https://stock-news.laohu8.com/highlight/detail?id=2635782592","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2635782592?lang=en_us&edition=fundamental","pubTime":"2026-05-13 20:30","pubTimestamp":1778675401,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260513:nPLXADB87B:4","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["FATE","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2635782088","title":"Fate Therapeutics Reports First Quarter 2026 Financial Results and Business Updates","url":"https://stock-news.laohu8.com/highlight/detail?id=2635782088","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2635782088?lang=en_us&edition=fundamental","pubTime":"2026-05-13 20:30","pubTimestamp":1778675400,"startTime":"0","endTime":"0","summary":"RECLAIM – LN, a Phase 2 potentially registrational clinical trial of FT819 in patients with refractory moderate-to-severe systemic lupus erythematosus (SLE) with lupus nephritis, on schedule to initia","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/05/13/3293996/24675/en/Fate-Therapeutics-Reports-First-Quarter-2026-Financial-Results-and-Business-Updates.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0795875086.SGD","LU1920062954.HKD","BK4504","BK4533","LU1221951046.USD","SG9999014559.SGD","LU1670711123.USD","SG9999014567.USD","BK4139","LU0098860793.USD","LU1894683348.USD","LU2746668974.SGD","SITC","LU0949170772.SGD","LU2237443622.USD","LU2133065610.SGD","LU0971096721.USD","BK4559","SG9999011175.SGD","LU0882574139.USD","IE00BVYPNW00.USD","LU2506951875.HKD","IE00B3PB1722.GBP","LU1894683264.USD","CAR","FATE","CMC","KO","LU0545039389.USD","BK4581","LU1868836591.USD","LU1868837136.USD","IND","LU2237443465.HKD","LU0096364046.USD","SLE","LU2125154935.USD","LU1920063259.USD","IE00BLSP4239.USD","LU0170899867.USD","LU1732799900.SGD","IE00BBT3K403.USD","IIM","LU0912757837.SGD","RA","BK4080","LU2125154778.USD","LU2347655156.SGD","LU0289960550.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2634890532","title":"Fate Therapeutics says FT819 achieves low disease activity in SLE without chemotherapy conditioning","url":"https://stock-news.laohu8.com/highlight/detail?id=2634890532","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2634890532?lang=en_us&edition=fundamental","pubTime":"2026-05-11 20:32","pubTimestamp":1778502750,"startTime":"0","endTime":"0","summary":"Fate Therapeutics presented new Phase 1 data at 2026 ASGCT showing its off-the-shelf CD19 CAR T-cell therapy FT819 produced clinical improvement in active systemic lupus erythematosus without conditioning chemotherapy.Responses were achieved with a single dose given alongside background therapy, supported by evidence of sustained B-cell depletion and reshaping consistent with disease control.Higher-dose dosing has started, setting up a near-term read on whether efficacy and durability extend with greater cell exposure while maintaining the safety profile seen to date.Additional ASGCT presentations will outline preclinical programs FT839 in autoimmune disease and FT836 in cancer, positioning both for broader use without conditioning chemotherapy and for combination strategies with standard-of-care agents.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260511:nNDL8KWZrL:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SG9999014021.USD","SG9999014013.SGD","SG9999014039.USD","BK4112","LU0314104364.USD","IE00BN0W2W23.USD","LU2210150020.SGD","BK4588","LU2095319765.USD","BK4585","IE00BN0W2T93.GBP","IE00BN0W2V16.EUR","IE00BGHQF748.EUR","IE00B3QW5Z07.USD","LU2210149790.SGD","BK4139","SG9999014005.SGD","IE00B64PRP62.GBP","NDAQ","FATE","IE00BKPKM429.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2633804455","title":"Fate Therapeutics Inc  expected to post a loss of 28 cents a share - Earnings Preview","url":"https://stock-news.laohu8.com/highlight/detail?id=2633804455","media":"Reuters","labels":["preview"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2633804455?lang=en_us&edition=fundamental","pubTime":"2026-05-08 19:54","pubTimestamp":1778241246,"startTime":"0","endTime":"0","summary":"Fate Therapeutics Inc  expected to post a loss of28cents a share - Earnings Preview Fate Therapeutics Inc FATE.OQ FATE.O is expected to  show a fall in quarterly revenue when it reports  results on Ma","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260508:nL8N41L16U:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"preview","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["FATE","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2633138399","title":"Piper Sandler Remains a Buy on Fate Therapeutics (FATE)","url":"https://stock-news.laohu8.com/highlight/detail?id=2633138399","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2633138399?lang=en_us&edition=fundamental","pubTime":"2026-05-06 19:59","pubTimestamp":1778068791,"startTime":"0","endTime":"0","summary":"Piper Sandler analyst Edward Tenthoff reiterated a Buy rating on Fate Therapeutics today and set a price target of $6.00. Tenthoff covers the Healt...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/piper-sandler-remains-a-buy-on-fate-therapeutics-fate-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/piper-sandler-remains-a-buy-on-fate-therapeutics-fate-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4139","FATE"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2633425948","title":"Fate Therapeutics Selected for U.S. FDA Chemistry, Manufacturing, and Controls Development and Readiness Pilot Program to Support Manufacturing Readiness of FT819","url":"https://stock-news.laohu8.com/highlight/detail?id=2633425948","media":"GlobeNewswire","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2633425948?lang=en_us&edition=fundamental","pubTime":"2026-05-05 20:30","pubTimestamp":1777984200,"startTime":"0","endTime":"0","summary":"FDA Chemistry, Manufacturing, and Controls (CMC) Development and Readiness Pilot (CDRP) program supports the acceleration of manufacturing readiness for therapies with expedited clinical development t","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/05/05/3287697/24675/en/Fate-Therapeutics-Selected-for-U-S-FDA-Chemistry-Manufacturing-and-Controls-Development-and-Readiness-Pilot-Program-to-Support-Manufacturing-Readiness-of-FT819.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU1363072403.SGD","IE00BZ1G4Q59.USD","LU2237443465.HKD","IE00BFXG1179.USD","LU0882574139.USD","CMC","BK4077","BK4230","LU0971096721.USD","LU2237443382.USD","LU2237443978.SGD","LU2237443549.SGD","IE00BHPRN162.USD","CAR","SLE","BK4588","BK4006","LU0149725797.USD","LABU","LU0267386448.USD","BK4139","IE00BKVL7J92.USD","LU2237443895.HKD","FATE","BK4585","BK4022","IE00B1BXHZ80.USD","LU2237443622.USD","LU0170899867.USD","LU2746668461.USD","LU2746668974.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2632955125","title":"Fate Therapeutics posts Phase 1 FT819 lupus data showing B-cell remodeling without chemo conditioning","url":"https://stock-news.laohu8.com/highlight/detail?id=2632955125","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2632955125?lang=en_us&edition=fundamental","pubTime":"2026-05-04 21:04","pubTimestamp":1777899856,"startTime":"0","endTime":"0","summary":"Fate Therapeutics outlined three ASGCT 2026 presentations highlighting off-the-shelf CAR T-cell candidates spanning autoimmune disease and oncology, with data scheduled for release May 11-15 in Boston.Clinical and translational results from Phase 1 FT819 in systemic lupus erythematosus will be presented in the future, focusing on B-cell remodeling without conditioning chemotherapy while patients remain on background maintenance therapy.FT839 will be discussed in a future oral session as a dual-target program intended to address difficult-to-treat autoimmune diseases by eliminating multiple pathogenic immune-cell populations while sparing non-activated cells.Preclinical FT836 data will be presented in the future, positioning the MICA/B-targeted program for broad anti-tumor activity without conditioning chemotherapy, with potential use alongside standard-of-care regimens.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT s","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260504:nNDL72Bz7B:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["FATE","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2632546955","title":"Fate Therapeutics Announces Three Presentations at the 2026 Asgct Annual Meeting Highlighting off-the-Shelf Car T-Cell Therapy Pipeline for Cancer and Autoimmune Diseases","url":"https://stock-news.laohu8.com/highlight/detail?id=2632546955","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2632546955?lang=en_us&edition=fundamental","pubTime":"2026-05-04 21:00","pubTimestamp":1777899602,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260504:nTUAVHLYQ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["FATE","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2632554409","title":"Fate Therapeutics Announces Three Presentations at the 2026 ASGCT Annual Meeting Highlighting Off-the-Shelf CAR T-cell Therapy Pipeline for Cancer and Autoimmune Diseases","url":"https://stock-news.laohu8.com/highlight/detail?id=2632554409","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2632554409?lang=en_us&edition=fundamental","pubTime":"2026-05-04 21:00","pubTimestamp":1777899600,"startTime":"0","endTime":"0","summary":"SAN DIEGO, May  04, 2026 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to bringing a transformative pipeline of induced pluripotent s","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/05/04/3286762/24675/en/Fate-Therapeutics-Announces-Three-Presentations-at-the-2026-ASGCT-Annual-Meeting-Highlighting-Off-the-Shelf-CAR-T-cell-Therapy-Pipeline-for-Cancer-and-Autoimmune-Diseases.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SLE","BK4077","BK4139","BK4230","BK4022","CAR","FATE"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2632930352","title":"Fate Therapeutics Is Maintained at Buy by HC Wainwright & Co.","url":"https://stock-news.laohu8.com/highlight/detail?id=2632930352","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2632930352?lang=en_us&edition=fundamental","pubTime":"2026-05-04 19:21","pubTimestamp":1777893660,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/FATE/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  May 04, 2026 07:21 ET (11:21 GMT)","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["FATE"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2632932837","title":"Fate Therapeutics price target raised to $7 from $5 at H.C. Wainwright","url":"https://stock-news.laohu8.com/highlight/detail?id=2632932837","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2632932837?lang=en_us&edition=fundamental","pubTime":"2026-05-04 18:17","pubTimestamp":1777889826,"startTime":"0","endTime":"0","summary":"H.C. Wainwright raised the firm’s price target on Fate Therapeutics (FATE) to $7 from $5 and keeps a Buy rating on the shares. The firm says FT819 ...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/fate-therapeutics-price-target-raised-to-7-from-5-at-h-c-wainwright-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/fate-therapeutics-price-target-raised-to-7-from-5-at-h-c-wainwright-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["FATE"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.fatetherapeutics.com","stockEarnings":[{"period":"1week","weight":-0.1382},{"period":"1month","weight":0.3237},{"period":"3month","weight":0.3143},{"period":"6month","weight":0.7864},{"period":"1year","weight":0.472},{"period":"ytd","weight":0.8726}],"compareEarnings":[{"period":"1week","weight":-0.0014},{"period":"1month","weight":0.0459},{"period":"3month","weight":0.0829},{"period":"6month","weight":0.1248},{"period":"1year","weight":0.2503},{"period":"ytd","weight":0.087}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"Fate Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops programmed cellular immunotherapies for cancer and immune disorders worldwide. Its chimeric antigen receptor (CAR)-targeted NK and T-cell product candidates include FT576 to treat multiple myeloma and FT522, to treat lymphoma and autoimmune disorders; and CAR T-cell programs include FT819 to treat hematologic malignancies and solid tumors, and FT825 to treat solid tumors. The company has a collaboration and option agreement with Ono Pharmaceutical Co. Ltd. for the development and commercialization of off-the-shelf, iPSC-derived CAR T-cell product candidates for the treatment of cancer. Fate Therapeutics, Inc. was incorporated in 2007 and is headquartered in San Diego, California.","yearOnYearQuotes":[{"month":1,"riseRate":0.538462,"avgChangeRate":0.049458},{"month":2,"riseRate":0.615385,"avgChangeRate":0.078089},{"month":3,"riseRate":0.461538,"avgChangeRate":-0.020579},{"month":4,"riseRate":0.615385,"avgChangeRate":0.004138},{"month":5,"riseRate":0.461538,"avgChangeRate":0.017799},{"month":6,"riseRate":0.5,"avgChangeRate":0.003206},{"month":7,"riseRate":0.416667,"avgChangeRate":0.050198},{"month":8,"riseRate":0.333333,"avgChangeRate":-0.024603},{"month":9,"riseRate":0.416667,"avgChangeRate":0.00072},{"month":10,"riseRate":0.25,"avgChangeRate":-0.091603},{"month":11,"riseRate":0.538462,"avgChangeRate":0.090829},{"month":12,"riseRate":0.538462,"avgChangeRate":0.045045}],"exchange":"NASDAQ","name":"Fate Therapeutics","nameEN":"Fate Therapeutics"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.42.2","shortVersion":"4.42.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Fate Therapeutics(FATE),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest Fate Therapeutics(FATE) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"Fate Therapeutics,FATE,Fate Therapeutics股票,Fate Therapeutics股票老虎,Fate Therapeutics股票老虎国际,Fate Therapeutics行情,Fate Therapeutics股票行情,Fate Therapeutics股价,Fate Therapeutics股市,Fate Therapeutics股票价格,Fate Therapeutics股票交易,Fate Therapeutics股票购买,Fate Therapeutics股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Fate Therapeutics(FATE),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest Fate Therapeutics(FATE) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}